

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28

IN THE UNITED STATES DISTRICT COURT  
FOR THE NORTHERN DISTRICT OF CALIFORNIA

KENNETH ARNOLD,

No. C 12-02115 WHA

Plaintiff,

v.

**ORDER DENYING SUMMARY  
JUDGMENT, ALLOWING  
LIMITED DISCOVERY AND  
VACATING HEARING**

BLUE SHIELD OF CALIFORNIA,

Defendant.

---

**INTRODUCTION**

In this ERISA action, defendant moves for summary judgment. Plaintiff opposes the motion and requests that judgment be entered in plaintiff's favor or, in the alternative, requests leave to take limited discovery. For the reasons explained below, defendant's motion is **DENIED**, plaintiff's request for judgment is **DENIED**, and plaintiff's request for leave to take limited discovery is **GRANTED**. The November 29 hearing is **VACATED**.

**STATEMENT**

"A.A.," daughter of plaintiff Kenneth Arnold, was covered under plaintiff's Blue Shield of California health insurance plan. Under the plan, if a subscriber obtains medical care from a non-participating provider, the subscriber pays for the treatment privately and then submits a claim to Blue Shield for reimbursement.

1           **1.       A.A.’S BACKGROUND.**

2           A.A. has been diagnosed with bipolar disorder, borderline personality disorder, and  
3           anorexia (AR 1781). Shortly after beginning college in 2009, she suffered a manic break and  
4           returned home for outpatient treatment with psychiatrist Lynn Ponton, M.D. During the  
5           outpatient therapy, which lasted from November, 2009, until March, 2010, Dr. Ponton indicated  
6           that A.A. was at a low “imminent risk of suicide or serious self-injury,” and that her condition  
7           had improved since returning from college (AR 143–83). Nevertheless, A.A.’s condition  
8           declined while she was being treated by Dr. Ponton. In March, 2010, Dr. Ponton raised the  
9           possibility of psychiatric hospitalization for A.A. (AR 1378–80). On April 2, 2010, Dr. Ponton  
10          wrote that A.A.’s expression of suicidality was “dangerous” and that her situation required “the  
11          constant monitoring and support of an intensive inpatient treatment program” (AR 1382).

12           **2.       ADMISSION TO MCLEAN HOSPITAL.**

13          On April 5, 2010, A.A. was admitted to a residential psychiatric treatment facility at  
14          McLean Hospital (AR 133–37). During her stay, A.A. made a suicide attempt using a shard of  
15          glass she found during a walk outside the facility (AR 1383–84). Her condition eventually  
16          improved, and she was discharged from the treatment facility on July 27, 110 days after she was  
17          admitted (AR 133–137).

18          The residential treatment facility was a self-pay program that did not participate in  
19          plaintiff’s Blue Shield insurance plan. Plaintiff paid \$115,000 out-of-pocket, which covered the  
20          full cost of treatment at McLean, and subsequently submitted a claim to defendant (AR 126–32,  
21          1685).

22           **3.       DENIAL OF THE CLAIM AND PLAINTIFF’S APPEAL.**

23          Defendant initially denied plaintiff’s claim as untimely, and plaintiff’s insurance broker  
24          initiated an appeal with defendant. Defendant chose not to rely on timeliness as a basis for  
25          denial, and instead assigned the appeal to Tim Ford, a senior clinical coordinator in its Appeals  
26          and Grievances Department (Ford Decl. ¶¶ 78–79). Mr. Ford reviewed the file with a nurse  
27          practitioner supervisor, and determined that a clinical review of the appeal would be necessary  
28          (*id.* ¶ 86).



1 discretion. *Montour v. Hartford Life & Acc. Ins. Co.*, 588 F.3d 623, 629 (9th Cir. 2009). Here,  
2 the Blue Shield plan agreement plainly states that Blue Shield has “the power and discretionary  
3 authority to . . . determine eligibility to receive Benefits under [the] Plan” (AR 60). This order  
4 finds that this language is sufficient to make an abuse of discretion standard of review the  
5 appropriate starting point.

6 When, however, the same entity that funds the plan also evaluates claims, the plan  
7 administrator faces a structural conflict of interest. *Id.* at 630. “Application of the abuse of  
8 discretion standard therefore requires a more complex analysis. . . . [And, ] a reviewing court  
9 must take into account the administrator’s conflict of interest as a factor in the analysis.” *Id.* at  
10 631 (citation omitted).

11 Other factors that affect the reasonableness of a plan administrator’s denial of benefits  
12 include:

13 the quality and quantity of the medical evidence, whether the plan  
14 administrator subjected the claimant to an in-person medical  
15 evaluation or relied instead on a paper review of the claimant’s  
16 existing medical records, whether the administrator provided its  
independent experts “with all of the relevant evidence[,]” and  
whether the administrator considered a contrary SSA disability  
determination, if any.

17 *Ibid.*

18 Defendant concedes that in this instance, the administrator functioned as both the  
19 decisionmaker as to benefits eligibility and the funding source of any benefits due, creating a  
20 structural conflict of interest (Br. 14). This conflict of interest is one factor that must be weighed  
21 in determining whether there has been an abuse of discretion.

22 This order finds that there is insufficient evidence in the administrative record to  
23 determine the weight of defendant’s conflict of interest. Defendant relied in part on a report  
24 from a third-party AMR reviewer who concluded that A.A.’s full stay at the residential treatment  
25 facility was not medically necessary. Yet, defendant also contends that the “ultimate decision as  
26 to the medical necessity of A.A.’s treatment” was made by Dr. Kato, a medical director at Blue  
27 Shield (Reply 10). Viewed in the light most favorable to the plaintiff, defendant’s own medical  
28 director may have a stronger predisposition toward improperly denying claims than the AMR

1 reviewer. The administrative record does not reveal the extent to which defendant based its final  
2 decision on the AMR report, as opposed to the judgment of Dr. Kato. This is sufficient to raise a  
3 genuine dispute as to how much weight to give defendant's conflict of interest.

4 **2. GENUINE DISPUTE REGARDING WHETHER BLUE SHIELD APPLIED THE PLAN**  
5 **DEFINITION OF MEDICAL NECESSITY.**

6 The parties also dispute whether defendant followed its own guidelines when it  
7 determined that A.A.'s continued residential treatment was not medically necessary.  
8 Defendant's plan contains a specific definition of medical necessity. The AMR reviewer's  
9 report states that under the "Milliman Guidelines," A.A. could have been treated at a lower level  
10 of care after ten days at the residential facility (AR 1783). These guidelines are separate from  
11 the Blue Shield plan and are not a part of the administrative record.

12 Defendant argues that even without these guidelines, all that matters is that the AMR  
13 reviewer reached this conclusion. Not so. Without the guidelines used by the AMR reviewer, it  
14 is not possible to determine whether the reviewer's methodology was consistent with the  
15 definition of medical necessity in the Blue Shield plan, or whether it was reasonable for  
16 defendant to rely on the reviewer's analysis. This lacuna is significant, and it precludes  
17 summary judgment.

18 **3. DEFENDANT'S FAILURE TO IDENTIFY ITS MEDICAL REVIEWER.**

19 At an August 23 case management conference, the Court urged defendant to provide the  
20 identity of the AMR reviewer to plaintiff. Nevertheless, defendant has failed to identify the  
21 name of the AMR doctor who reviewed the appeal. ERISA's plain language states that a  
22 "reasonable opportunity for a full and fair review of a claim" requires "identification of medical  
23 or vocational experts whose advice was obtained on behalf of the plan in connection with a  
24 claimant's adverse benefit determination." C.F.R. § 2560.503-1(h)(3).

25 Plaintiff complains that without the identify of the reviewer, questions such as whether  
26 the reviewer is actually board certified, or whether the reviewer has ever been suspended from  
27 practice by a medical board cannot be answered. The Court agrees. Viewed in the light most  
28 favorable to the plaintiff, the answers to these questions may show whether defendant reasonably

1 relied on the AMR reviewer’s conclusions, and whether defendant adequately investigated  
2 plaintiff’s claim.

3 Defendant contends that the practice of not identifying third-party reviewers by name is  
4 “regularly approved by the courts” (Reply Br. 10). How counsel could have gleaned this  
5 proposition from *Simonia v. Glendale Nissan/Infiniti Disability Plan*, *Lukas v. United Behavioral*  
6 *Health*, and *Gaines v. Guardian Life Insurance Company of America* is a mystery to the Court.  
7 In *Simonia*, our court of appeals assumed without deciding that the failure to identify a medical  
8 reviewer violates ERISA. *Simonia v. Glendale Nissan/Infiniti Disability Plan*, 378 Fed. App’x  
9 725, 727 (9th Cir. 2010). The district courts in *Lukas* and *Gaines* both affirmatively concluded  
10 that ERISA requires disclosure of the name of a reviewer. *Lukas v. United Behavioral Health*,  
11 No. 09-2423, 2011 WL 1459157, at \*17 (E.D. Cal. Apr. 15, 2011) (“The Plan Administrator did  
12 not provide the name of the physician to plaintiffs. This resulted in a violation of ERISA  
13 procedures.”); *Gaines v. Guardian Life Ins. Co. of Am.*, No. 09-1762, 2010 WL 1759579, at \*7  
14 (D. Md. Apr. 30, 2010) (“[T]he Court believes that the statute’s plain language requiring  
15 identification of a medical consultant compels an administrator to reveal more than merely the  
16 consultant’s qualifications.”).

17 These cases do not approve of withholding the identity of a third-party reviewer. Rather,  
18 they recognize that a failure to identify a medical reviewer violates ERISA, and that any  
19 resulting prejudice to the plaintiff is a factor that should be considered by a reviewing court. In  
20 the absence of prejudice, a plan administrator may have substantially complied with ERISA  
21 despite failing to properly disclose the name of a medical reviewer. Whether plaintiff has in fact  
22 suffered any prejudice from defendant’s refusal to provide this information remains to be seen.

23 **4. PLAINTIFF’S REQUEST FOR DISCOVERY.**

24 As explained above, there are unanswered questions as to defendant’s conflict of interest,  
25 defendant’s basis for denying plaintiff’s claim, the methodology employed in evaluating the  
26 claim, and the role of the AMR reviewer. Defendant has also failed to identify its AMR  
27 reviewer. Whether this refusal has prejudiced plaintiff is unknown. Some discovery is  
28 warranted within this limited scope.

1 Plaintiff has also requested discovery into the third-party reviewer's track record for  
2 approving claims, and communications with defendant during the review process. This Court  
3 has previously found that discovery into the possible bias and track records of third-party  
4 reviewers may be appropriate in ERISA cases. *See, e.g., Tarasovsky v. Stratify, Inc. Group*  
5 *Short and Long Term Disability Plan*, No. 11-3359, 2012 WL 1831507, at \*6 (N.D. Cal. May  
6 18, 2012) (Alsup, J.); *Carten v. Hartford Life and Acc. Ins. Co.*, No. 10-4019, 2011 WL 768683,  
7 at \*4 (N.D. Cal. Feb. 28, 2011) (Alsup, J.). Within reasonable limits, discovery regarding the  
8 AMR reviewer's possible bias and track record will be allowed.

9 **CONCLUSION**


10 The parties' cross-motions for summary judgment are **DENIED** without prejudice. The  
11 November 29 hearing is **VACATED**.

12 The following limited discovery regarding the basis for the AMR reviewer's decision, the  
13 AMR reviewer's possible bias and track record, defendant's conflict of interest, and defendant's  
14 basis for denying the claim will be allowed. Plaintiff may serve ten narrow interrogatories  
15 without sub-parts and fifteen document requests that are narrowly drawn. Plaintiff may also take  
16 five one-day depositions. Discovery related to bias and conflict of interest is not limited to  
17 A.A.'s specific case. The discovery may not be used to supplement the record with additional  
18 medical documentation supporting plaintiff's claim.

19 This discovery must be completed by **MARCH 31, 2013**. A case management conference  
20 will be held at **11:00 A.M. ON APRIL 4, 2013**, in order to set an evidentiary hearing or determine  
21 how else to proceed.

22  
23  
24 **IT IS SO ORDERED.**

25  
26 Dated: November 26, 2012.

27   
28 \_\_\_\_\_  
WILLIAM ALSUP  
UNITED STATES DISTRICT JUDGE